Ken Griffin Inhibrx, Inc. Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$32.76 - $39.56 $31.1 Million - $37.6 Million	949,414 Added 372.56%	1,204,252 $42.1 Million
Q4 2023 Feb 14, 2024	BUY	$14.5 - $38.0 $174,406 - $457,064	12,028 Added 4.95%	254,838 $9.68 Million
Q3 2023 Nov 14, 2023	BUY	$15.75 - $26.31 $2.77 Million - $4.63 Million	175,999 Added 263.43%	242,810 $4.46 Million
Q2 2023 Aug 14, 2023	BUY	$16.96 - $27.82 $801,054 - $1.31 Million	47,232 Added 241.24%	66,811 $1.73 Million
Q1 2023 May 15, 2023	SELL	$18.45 - $27.14 $725,601 - $1.07 Million	-39,328 Reduced 66.76%	19,579 $369,000
Q4 2022 Feb 14, 2023	BUY	$20.18 - $33.33 $98,740 - $163,083	4,893 Added 9.06%	58,907 $1.45 Million
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $109,801 - $234,489	9,482 Added 21.29%	54,014 $969,000

18.6K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $570M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.